ALIGOS THERAPEUTICS INC (ALGS)

Company Profile

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 68 full-time employees. The company went IPO on 2020-10-16. The company uses its small molecule and oligonucleotide platforms to develop pharmacologically optimized drug candidates for use in combination regimens. Its primary area of focus is on developing functional cure for nonalcoholic steatohepatitis (NASH) and to develop drug candidates with coronavirus activity, as well as seeks to enhance the rate of functional cure for chronic hepatitis B (CHB). The company has developed a portfolio of differentiated drug candidates for CHB, including a small molecule capsid assembly modulator (CAM-E) and oligonucleotide small interfering ribonucleic acids (siRNA), each of which is designed against clinically validated targets in the hepatitis B virus (HBV) life cycle. Its pipeline includes ALG-055009 for the treatment of NASH; ALG-000184 and ALG-125755 for CHB, and ALG-097558 for coronavirus.

Company Info

ALIGOS THERAPEUTICS INC

One Corporate Dr., 2Nd Floor, 2nd Floor

South San Francisco CALIFORNIA 94080

P: 18004666059.0

CEO: Lawrence M. Blatt

Employees: 68

Website: https://www.aligos.com/